Pretzel Gets $72.5M for Gene Editing & Small Molecules Against Mitochondrial Targets

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D
Investing in Manufacturing, Mental Health & More: Bob Nelsen on The Long Run
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?